Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR)

Oppenheimer assumed coverage on shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in a research report sent to investors on Friday, MarketBeat.com reports. The firm issued an outperform rating and a $15.00 target price on the biopharmaceutical company's stock.

PRQR has been the topic of several other reports. Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Raymond James upgraded ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. StockNews.com downgraded ProQR Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, November 28th. JMP Securities restated a "market outperform" rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, ProQR Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

ProQR Therapeutics Stock Performance

PRQR stock traded down $0.20 on Friday, hitting $2.42. 346,939 shares of the company's stock were exchanged, compared to its average volume of 267,607. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62. The firm has a 50 day moving average price of $3.23 and a two-hundred day moving average price of $2.51. The stock has a market cap of $197.67 million, a P/E ratio of -7.56 and a beta of 0.30.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of PRQR. Privium Fund Management B.V. lifted its holdings in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock valued at $10,251,000 after buying an additional 51,663 shares during the period. OneDigital Investment Advisors LLC raised its holdings in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 15,550 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 7,300 shares during the period. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).